Alzheimer’s Clinical Trials for Seniors

Research partners include Harvard University, Johns Hopkins University, University of Southern California, Eli Lilly, Eisai, Biogen and many others.

Our Alzheimer’s clinical trials for seniors employ the latest methodologies and are based on the most encouraging theories. By joining other participants, you are helping develop medical treatments as well as breakthrough technologies.

We cover participants’ clinical trial costs, offer access to our other memory care programs and, in some cases, compensation may be available for time and travel.

If you are interested in participating or learning more about our Alzheimer’s clinical trials for seniors, please call 305.514.8710 or complete the form below.

CURRENT CLINICAL TRIALS

Clinical Trial of Piromelatine 20mg (Neurim Pharmaceuticals)

• Study Description: To evaluate the safety and efficacy of Piromelatine vs. placebo in modifying Alzheimer’s Disease progression
• Diagnosis: Mild Alzheimer’s Disease
• Ages: 50 – 80 years of age

Clinical Trial of Simufilam (Cassava Sciences)

• Study Description: To evaluate the safety and efficacy of Simufilam vs. placebo for treatment of Alzheimer’s Disease
• Diagnosis: Mild to moderate Alzheimer’s Disease
• Ages: 50 – 87 years of age

Nicotine Treatment (Vanderbilt University and University of Southern California)

• Study Description: To test whether a nicotine patch will produce long-term cognitive benefits
• Diagnosis: Mild cognitive impairment/ No Alzheimer’s Disease
• Ages: 55 – 90 years of age

Clinical Trial of Dronabinol (John’s Hopkins University)

• Study Description: To evaluate the safety and efficacy of Dronabinol for treating agitation related to Alzheimer’s Disease
• Diagnosis: Alzheimer’s Disorder and agitation
• Ages: 60 – 90 years of age

Clinical Trial for Treatment of Agitation (Avanir Pharmaceuticals)

• Study Description: To evaluate the safety and efficacy of deudextromethorphan hydrobromide mixed with quinidine sulfate for treating agitation in patients with Alzheimer’s Disease
• Diagnosis: Agitation in Alzheimer’s Disease
• Ages: 50 – 90 years of age

 Clinical Trial for Dementia-Related Apathy (Cerevel Therapeutics)

• Study Description: To evaluate the safety and efficacy of CVL-871 for treating apathy related to dementia
• Diagnosis: Dementia with apathy
• Ages: 50 – 85 years of age

Clinical Trial for Treatment of Psychosis associated with Alzheimer’s (Karuna Therapeutics)

• Study Description: To evaluate the safety and efficacy of xanomeline mixed with trospium for treating Psychosis associated with Alzheimer’s Disease Dementia
• Diagnosis: Psychosis in Alzheimer’s Disease
• Ages: 55 – 90 years of age

Clinical Trial of Masupirdine to Treat Agitation (Suven Life Sciences)

• Study Description: To evaluate the safety and efficacy of Masupirdine for treating agitation related to Alzheimer’s Disease
• Diagnosis: Agitation in dementia related to Alzheimer’s Disease
• Ages: 50 – 90 years of age

Clinical Trial of Valbenazine for Schizophrenia (Neurocrine Biosciences)

• Study Description: To evaluate the safety and efficacy of Valbenazine, in addition to regular medication, on symptoms of schizophrenia
• Diagnosis: Schizophrenia
• Ages: 18+ years of age

 Microbiome in Gut and Brain Study

• Study Description: To understand the difference in the microbiome between participants with mild cognitive impairment and Alzheimer’s Disease compared with those with no memory problems
• Diagnosis: No cognitive impairment, mild cognitive impairment, or Alzheimer’s Disease
• Ages: 60+ years of age